Joining forces to commercialize technologies for the operating room of the 21st century, the two companies are calling their venture OR21. OR21 is a fresh approach to improving patient safety and surgical team efficiency in surgical environments – at the same time enhancing profitability for healthcare institutions. In developing their technologies, the two companies interviewed surgeons, nurses and radiologists regarding what they need to be successful and also spent hundreds of hours observing ORs in action. The companies’ joint venture signifies a commitment to stimulating change in operating rooms by offering advanced technologies that address the needs of clinicians and improve patient outcomes.
As worldwide challenges relating to healthcare access, cost and quality are placing a greater spotlight on the performance and accountability of operating rooms. The collaboration between American Shared Hospital Services and NBBJ will showcase what can be accomplished when leading companies with complementary capabilities work together toward a shared goal. The two companies have seeded OR21 with an array of patented and patent-pending technologies that have substantial revenue potential, from new operating room lighting concepts to innovative operating table design. The companies are in the midst of discussions with a third party regarding licensing agreements for manufacturing and distributing products based on these proprietary technologies. The initial product launch is expected to take place in late 2013.
Committed to improving health on a global scale through facility innovation, NBBJ has designed state-of-the-art facilities for leading healthcare institutions that include 10 of the top 17 U.S. News and World Report Honor Roll hospitals, as well as headquarters for top corporations like Reebok, Microsoft, and Starbucks.
Providing turnkey technology solutions for advanced radiosurgical and radiation therapy services, American Shared Hospital Services is a leading global provider of gamma knife radiosurgery equipment, which is a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia. The company also offers the latest IGRT and IMRT systems and owns a preferred stock investment in Mevion Medical Systems, Inc. (formerly Still River Systems), developer of the MEVION S250 proton beam radiation (PBRT) system, not yet approved by the FDA.
For more information, visit www.ashs.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
